agios

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy OfficerAgios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

March 05, 2025 17:52 ET  | Source: Agios Pharmaceuticals, Inc. CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals,…

1 week ago
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivatat ASH 2024 and Provides Regulatory Update on MitapivatAgios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivatat ASH 2024 and Provides Regulatory Update on Mitapivat

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivatat ASH 2024 and Provides Regulatory Update on Mitapivat

– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – –…

3 months ago